▌The successful convening of 16thCPhI China

    Up to 2000, Chinese APIs trade has gone through fifteen-year-long hardships. CPhI China roots in Chinese pharmaceutical industry, face with the international cutting-edge fields and guide so many pharmaceutical companies to become bigger and stronger. It also embraced the sixteenth year of making out mew achievements.

    From June21stto23rd, 2016, the "Sixteenth CPhI China", together with the "Eleventh P-MEC China" were powerfully launched at Shanghai New International Expo Center.

▌Theme of "Year of Central and Eastern Europe"

    In 2016, focused on the regions along New Silk Road Economic Belt, CPhI& P-MEC carried out series of activities on the theme of “Year of Central and Eastern Europe” to promote the communications of China and Central and Eastern Europe countries on the fields of medicine and healthcare and the pragmatic cooperation between pharmaceutical enterprises of both sides.

    With meticulous organization and planning of the sponsor, delegations from sixteen Central and Eastern Europe countries and representatives of Chinese pharmaceutical entrepreneurs got together to explore cooperation opportunities one day before the exhibition. On June21st, Ministry of Health and representatives of enterprises from sixteen Central and Eastern Europe countries arrived at the exhibition scene to have a visit; and attended the on-site negotiation symposium between China and Central and Eastern Europe enterprises to offer optimal chances for their trade cooperation.

▌Participation in Exhibition of “Minxiang Biomedical” with Its Advantages and Plentiful Rewards

    Under the grand pattern of healthcare and environmental protection industries’ explosion, Tianjin Minxiang Biomedical Inc. devotes to research and develop and produce series products of adamantaneand provide superior-quality and high-efficient products for numerous domestic and overseas industry magnates on medical treatment and car environmental protection processes all the time. At the end of 2015, Tianjin Minxiang Biomedical Inc. (stock short name “Minxiang Biomedical”, stock code: 834738) was listed on New Three Board to officially launch its new attempt in capital market.

    At the exhibition, the presentation of “Year of Central and Eastern Europe” corresponded to strategic development planning for overseas salesmarket expansion of Minxiang Biomedical. During the three-day-long exhibition, Minxiang Biomedical fully demonstrated the advantages of its products and was highly appreciated by lots of exhibitors. At the same time, we grasped the latest development trend of medical markets and won numerous opportunities for market cooperation.

    Minxiang Biomedical would stick to the development concept of “Aspire to Innovations, and Innovate the Quality”, research and produce more advanced products, take precise scientific and technological innovations as our backup force to deeply cultivate the pharmaceutical and chemical industry markets, and make further progress on the basis of current achievements.